Compounds > zalcitabine
Page last updated: 2024-08-22

zalcitabine and vrx-480773

zalcitabine has been researched along with vrx-480773 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P1
Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1

Other Studies

4 other study(ies) available for zalcitabine and vrx-480773

ArticleYear
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication

2011
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
    Bioorganic & medicinal chemistry, 2012, Sep-15, Volume: 20, Issue:18

    Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication

2012
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23

    Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines

2012
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
    Bioorganic & medicinal chemistry, 2012, Dec-01, Volume: 20, Issue:23

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide

2012